CAS: 1227158-85-1 - 1-Cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]piperazine
Formula:C26H26F3N7O2
InChI:InChI=1S/C26H26F3N7O2/c1-17-14-22(25-31-24(33-38-25)19-2-6-21(7-3-19)37-26(27,28)29)32-36(17)16-18-8-9-30-23(15-18)35-12-10-34(11-13-35)20-4-5-20/h2-3,6-9,14-15,20H,4-5,10-13,16H2,1H3
InChI key:InChIKey=CDJNNOJINJAXPV-UHFFFAOYSA-N
SMILES:FC(F)(F)OC=1C=CC(=CC1)C2=NOC(=N2)C3=NN(C(=C3)C)CC=4C=CN=C(C4)N5CCN(CC5)C6CC6
- Synonyms:
- 1-Cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]piperazine
- Piperazine, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-
- BAY 87-2243
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
BAY 87-2243 REF: IN-DA009C99CAS: 1227158-85-1 | 98% | 64.00 €~531.00 € | Tue 21 Jan 25 | |
BAY 87-2243 REF: TM-T2488CAS: 1227158-85-1 | 98% - 99.77% | 45.00 €~643.00 € | Mon 27 Jan 25 | |
BAY 87-2243 REF: TR-B119070CAS: 1227158-85-1 | - - - | 9,038.00 € | Fri 28 Feb 25 | |
BAY 87-2243-d8 REF: TR-B119072CAS: 1227158-85-1 | - - - | 13,546.00 € | Fri 28 Feb 25 | |
BAY 87-2243-d8 REF: 3D-CZB15885CAS: 1227158-85-1 | Min. 95% | - - - | Discontinued product |
BAY 87-2243
Ref: IN-DA009C99
5mg | 64.00 € | ||
10mg | 83.00 € | ||
25mg | 132.00 € | ||
50mg | 149.00 € | ||
100mg | 237.00 € | ||
250mg | 531.00 € |
BAY 87-2243
Ref: TM-T2488
2mg | 45.00 € | ||
5mg | 65.00 € | ||
10mg | 105.00 € | ||
25mg | 219.00 € | ||
50mg | 424.00 € | ||
100mg | 643.00 € | ||
1mL*10mM (DMSO) | 77.00 € |
BAY 87-2243
Controlled ProductRef: TR-B119070
1g | 9,038.00 € |
BAY 87-2243-d8
Controlled ProductRef: TR-B119072
250mg | 13,546.00 € |
BAY 87-2243-d8
Ref: 3D-CZB15885
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information |